Aug 2026· ecancermedicalscience· Vol 20· 0 citations· 9 references
TL;DR
A core set of genes, including topoisomerase II alpha, maternal embryonic leucine zipper kinase, BIRC5 and abnormal spindle-like microcephaly, which are consistently upregulated in tumours but do not significantly predict patient survival are identified.
Abstract
Glioblastoma (GBM) is a highly aggressive brain cancer with poor patient outcomes. This study uses a multi-step approach to identify reliable genetic markers for the disease. First, we analysed the GSE4290 dataset, comparing 77 tumour samples to 23 healthy brain controls to identify significantly overexpressed genes. To ensure these findings were not specific to a single study, we validated our results using the GSE147352 dataset. Finally, we correlated these gene expression levels with clinical outcomes using survival data from The Cancer Genome Atlas. Our results identified a core set of genes, including topoisomerase II alpha, maternal embryonic leucine zipper kinase, BIRC5 and abnormal spindle-like microcephaly (ASPM), which are consistently upregulated in tumours but do not significantly predict patient survival. These findings provide a validated molecular signature that defines the GBM transcriptome, though its clinical impact appears decoupled from overall survival, likely due to intensive treatment protocols or other dominant biological factors.
It is demonstrated that immune-related hallmark pathway activity contributes substantially to glioblastoma biological heterogeneity and patient prognosis, and the proposed pathway-based prognostic framework provides a biologically interpretable approach for survival stratification.
Ahmed M. Abdelmaguid, Rasha M. A. Eltanany, Manal F. El-khadragy et al.· Discover Oncology· 0 citations
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults, characterized by rapid progression and high resistance to conventional therapies. Recent studies on differential gene expression have contributed to a deeper understanding of the molecular mechanisms underlying its pathogenes...
Luciana Dai Pra Penteado, J. Marcon, Scheila de Avila e Silva· Revista de Estudos Interdisc...· 0 citations
BACKGROUND
Gliomas are molecularly heterogeneous central nervous system tumors with marked variation in clinical outcome. Alzheimer's disease (AD)-associated transcriptional alterations may capture neural and immune programs relevant to glioma biology, but they do not by themselves establish a direct mechanistic relati...
Jun-Wu Fu, Xiang-Qian Ren, Cheng-Yong Yang et al.· Brain Research· 0 citations
Introduction
. Glioblastoma is characterized by marked molecular heterogeneity and aggressive biologic behavior, which requires reliable molecular biomarkers for prognostic stratification. The aim of this study is to identify potential prognostic biomarkers for glioblastoma through integrated bioinformatic and prote...
I. Gareev, O. Beylerli, S. Roumiantsev· Creative Surgery and Oncolog...· 0 citations
Colorectal cancer (CRC) remains a leading cause of cancer mortality. This study investigates the prognostic and immunological role of neural-related genes (NRGs) in CRC. Using The Cancer Genome Atlas (TCGA) data, a four-gene signature (POU4F1, KLC3, ATP2A1, CALB2) was constructed via Cox and least absolute shrinkage an...
MZT1 is a proliferation-associated marker that integrates clinical risk, transcriptional programs, cellular heterogeneity, and predictive modeling in LUAD, providing a potential framework for biomarker development and risk stratification.
Dahlak Daniel Solomon, Hui-Ru Lin, Yung-Kuo Lee et al.· Cancer Genomics & Proteomics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
